Sana Biotechnology Q3 net loss narrows

Sana Biotechnology

06/11/2025 22:07

Overview

Sana Biotechnology Q3 net loss of $42.2 mln, with operating expenses of $43.5 mln

Raised $115.8 mln from stock sales, cash position at $153.1 mln

Company prioritizes SC451 and SG293, suspends other CAR T programs

Result Drivers

TYPE 1 DIABETES FOCUS - Sana prioritizes SC451 development due to promising clinical results and regulatory progress

R&D expenses were $35.5 million  for the three  ended September 30, 2025, compared to $12.4 million  for the same periods in 2024

Cash, cash equivalents, and marketable securities as of September 30, 2025 were $153.1 million compared to $152.5 million as of December 31, 2024.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$42.15 mln
Q3 Operating Expenses
$43.52 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Sana Biotechnology Inc is $8.00, about 49% above its November 5 closing price of $4.08

Press Release: ID:nGNXb0j1P2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)